323 related articles for article (PubMed ID: 34944858)
1. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment.
Tymon-Rosario J; Adjei NN; Roque DM; Santin AD
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944858
[TBL] [Abstract][Full Text] [Related]
2. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
4. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
5. Novel cytotoxic agents: epothilones.
Goodin S
Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
[TBL] [Abstract][Full Text] [Related]
6. Epothilones in the treatment of ovarian cancer.
Diaz-Padilla I; Oza AM
Future Oncol; 2011 Apr; 7(4):559-68. PubMed ID: 21463144
[TBL] [Abstract][Full Text] [Related]
7. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
Rosenberg JE; Galsky MD; Rohs NC; Weinberg VK; Oh WK; Kelly WK; Small EJ
Cancer; 2006 Jan; 106(1):58-62. PubMed ID: 16329138
[TBL] [Abstract][Full Text] [Related]
8. Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review.
Zagouri F; Sergentanis TN; Chrysikos D; Dimopoulos MA; Bamias A
Onco Targets Ther; 2015; 8():2187-98. PubMed ID: 26316786
[TBL] [Abstract][Full Text] [Related]
9. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
[TBL] [Abstract][Full Text] [Related]
11. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
Bhushan S; Walko CM
Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
[TBL] [Abstract][Full Text] [Related]
12. RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.
Vishnu P; Colon-Otero G; Kennedy GT; Marlow LA; Kennedy WP; Wu KJ; Santoso JT; Copland JA
Gynecol Oncol; 2012 Mar; 124(3):589-97. PubMed ID: 22115851
[TBL] [Abstract][Full Text] [Related]
13. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
Goodin S
Am J Health Syst Pharm; 2008 Nov; 65(21):2017-26. PubMed ID: 18945860
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with epothilones in patients with breast cancer.
Buzdar AU
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
De Geest K; Blessing JA; Morris RT; Yamada SD; Monk BJ; Zweizig SL; Matei D; Muller CY; Richards WE
J Clin Oncol; 2010 Jan; 28(1):149-53. PubMed ID: 19917861
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones.
Pronzato P
Drugs; 2008; 68(2):139-46. PubMed ID: 18197722
[TBL] [Abstract][Full Text] [Related]
17. Profile and potential of ixabepilone in the treatment of pancreatic cancer.
Smaglo BG; Pishvaian MJ
Drug Des Devel Ther; 2014; 8():923-30. PubMed ID: 25075175
[TBL] [Abstract][Full Text] [Related]
18. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
19. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
20. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
Dumontet C; Jordan MA; Lee FF
Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
